Novogene offers CLIA-validated Whole Exome Sequencing (WES) for investigation or diagnoses of genetic variations underlying cancers, Mendelian diseases, and complex human disorders.
Whole Exome Sequencing is gaining popularity as a viable and cost-effective alternative to Whole Genome Sequencing: WES targets all protein-coding regions (~1% of the whole genome) responsible for 85% of all disease-causing mutations.
Service Features
Clinical WES Workflow
Performance Metrics
Download Brochure to Learn More
Contact Us / Request Quote
I agree that Novogene Corporation may use this information to contact me to assist with my request. I understand that all personal information I have submitted will be kept confidential in accordance with Novogene's privacy policy.
8801 Folsom Blvd #290, Sacramento, CA 95826
Copyright©2011-2020 Novogene Corporation All Rights Reserved. Information and specifications are subject to change at any time without notice.
We use cookies to enhance your browsing experience. To learn more please see our Privacy Policy
By continuing you agree to our use of cookies.
The field is required.